(February 13, 2020) PARP inhibitors have shown to be a promising treatment option for a subset of ovarian cancer patients. As of February 2020, there are currently 3 FDA-approved PARP inhibitors for ovarian cancer: olaparib (Lynparza), niraparib (Zejula), and rucaparib (Rubraca).
In an interview with OncLive, Dr. Robert Coleman, a member of OCRA’s Scientific Advisory Committee, talks about how the role of PARP inhibitors have evolved for ovarian cancer treatment over the years, with particular focus on rucaparib which received FDA approval in April 2018. Dr. Coleman discusses results seen from patients using rucaparib for treatment, as well as drug toxicities, how rucaparib compares to other PARP inhibitors on the market, and what’s up and coming in the PARP inhibitor landscape.
Read the full interview, conducted by OncLive at the 2020 Society of Gynecologic Oncology (SGO) Winter Meeting.
Learn more about PARP Inhibitors for ovarian cancer treatment:
- Explore all PARP Inhibitor research funded by OCRA
- Download our webinar, “PARP Inhibitors: What You Need to Know.”